Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3064695 | Journal of Neuroimmunology | 2010 | 5 Pages |
Abstract
Multiple Sclerosis (MS) is a genetically complex immune mediated, demyelinating disease of the central nervous system. To date no genetic variants have been unambiguously linked to disease severity. We have conducted a genome wide screen, using Affymetrix Genechip® 500K technology, for severity in 1040 MS patients. Two markers within MGAT5, a gene coding for a glycosylation enzyme, were found to be significantly associated with outcome in the screening as well as in an independent population (combined p-values: 2.8 × 10− 6 and 1.5 × 10− 7).
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
B. Brynedal, J. Wojcik, F. Esposito, V. Debailleul, J. Yaouanq, F. Martinelli-Boneschi, G. Edan, G. Comi, J. Hillert, H. Abderrahim,